医药行业周报（2024年第52周）

Industry Overview - The pharmaceutical and biological industry experienced a weekly decline of -2.1%, ranking 13th among the 31 Shenwan primary industries, with a weekly turnover of 3456.19 billion yuan [29] - Among the secondary industries, Traditional Chinese Medicine II (TCM II) had the smallest decline at -0.6%, while Chemical Pharmaceuticals had the largest decline at -2.8% [30] - Chemical Pharmaceuticals had the highest weekly turnover at 1098.8 billion yuan, while Biological Products had the lowest at 281.49 billion yuan [13] - Chemical Pharmaceuticals also had the highest turnover rate at 10.9%, with a turnover rate percentile of 81.5%, whereas Biological Products had the lowest turnover rate at 4.9%, with a percentile of 35.6% [13] - The price-to-earnings ratio (TTM) for Chemical Pharmaceuticals was the highest at 37.2x, while the price-to-book ratio percentile for TCM II was the highest at 36.5% [13] Industry News and Announcements - The National Medical Products Administration (NMPA) released a draft announcement to simplify the registration and approval process for traditional oral Chinese medicines from Hong Kong and Macau to enter the mainland market, potentially reducing the technical review period from 200 to 80 working days [16] - Five departments, including the National Health Commission and the Ministry of Civil Affairs, issued guidelines to promote high-quality development of integrated medical and elderly care services, supporting the inclusion of eligible medical and elderly care institutions in the scope of medical insurance coverage [17][19] - Yifan Pharmaceutical's subsidiary received approval from the Brazilian Health Regulatory Agency (ANVISA) for the marketing of its product Ryzneuta®, marking a significant milestone in the company's expansion into the Latin American market [20] - China Pharmaceutical's subsidiary, Tianfang Pharmaceutical, received approval from the NMPA for its generic drug Nicorandil Tablets, which passed the consistency evaluation for generic drug quality and efficacy, potentially increasing its market share [31] - Jointown Pharmaceutical's subsidiary received approval from the NMPA for the marketing application of L-Malic Acid, which is expected to enhance the company's product line and competitiveness in the pharmaceutical industry [32] Market Performance - The pharmaceutical and biological industry underperformed major market indices, with the Shanghai Composite Index down -0.7%, the Shenzhen Component Index down -0.6%, the CSI 300 down -0.1%, and the Wind All-A Index down -1.1% [29] - Among the secondary industries, TCM II had the smallest weekly decline at -0.6%, while Chemical Pharmaceuticals had the largest decline at -2.8% [30] - The turnover rate percentile for Medical Services was the highest at 90.8%, while Biological Products had the lowest at 35.6% [13]